Abstract
Introduction
HIV/AIDS stands out as a highly lucrative and expanding market for diagnostics
companies because of the close integration of diagnostics in initial diagnosis
and subsequent day-to-day disease management. With the newly released CDC
screening recommendations advocating increased testing for the infection,
diagnostics will play an increasingly critical role in HIV disease management.
Get the Answers You Need to Shape Your Strategy
- The revised CDC guidelines for HIV testing are set to dramatically benefi
t the HIV diagnostics market in the
- United States. Which sectors of the diagnostics market will benefi t most?
What will be the long-term
- impact of the CDC recommendations?
- The new recommendations have changed HIV testing from an
“opt-in” diagnostic to an “opt-out” test that is
- a routine part of medical practice. How will this new process affect the
diagnosis rates for HIV? Will it
- dramatically increase treatment rates?
- HIV diagnosis is currently a multistep process that involves
time-consuming confi rmatory tests. In its new
- recommendations, the CDC advocates the use of rapid testing. How will the
CDC recommendations impact
- the rapid testing arena? Which companies are the key players in this
sector?
- With the increase in drug resistance among HIV/AIDS patients, resistance
testing is playing a growing role in
- HIV disease management. Will the new CDC recommendations increase use of
monitoring tests as well?
- What unmet needs remain in the resistance testing sector? Which companies
are active in this area?
Scope
- Discussion of new CDC recommendations: revisions, rationale, target
populations, and response to changes.
- Current HIV diagnostics: screening, confi rmatory, and monitoring tests.
- Emerging HIV diagnostics: home test kits, replication capacity tests, and
CCR5 and CXCR4 tests.
- Key players: profi les of select leaders in HIV diagnostics.
- Outlook for HIV diagnostics: impact of CDC guidelines on diagnostics and
on drug treatment,
- constraints on routine testing, and strategic considerations.
Mentioned in This Spectrum Report
Companies:
- Abbott Laboratories
- Beckman Coulter
- Becton Dickinson
- BioMerieux
- Bio-Rad Laboratories
- Bristol-Myers Squibb
- Calypte Biomedical
- Celera Diagnostics
- Chembio Diagnostic Systems
- Gen-Probe
- Gilead Sciences
- GlaxoSmithKline
- Guava Technologies
- Home Access Health
- LabCorp
- MedMira Laboratories
- Monogram Biosciences
- Murex Diagnostics
- OraSure Technologies
- Partec
- pfizer
- Roche Molecular Diagnostics
- Siemens Medical Solutions
- Diagnostics
- Specialty Laboratories
- Trinity Biotech
- Virco
- ViroLogic
- Visible Genetics
- Waldheim Pharmazeutika
View Cart
